Medicare Enrolled
Dr. Michael Seidman, MD
Hematology & Oncology · Horsham, PA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Seidman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Seidman?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Seidman
Dr. Michael Seidman is a hematology & oncology specialist in Horsham, PA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Seidman performed 112,062 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Seidman received a total of $37,858 from 49 pharmaceutical and/or device companies across 192 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Seidman is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years of NPI registration
▲ Top 5% volume in PA
$37,858 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗112,062
Medicare services
Top 5% in PA for hematology & oncology
Not available
Unique patients (not deduplicated)
$11
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
55,100 | $2 | $21 |
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
23,250 | $1 | $4 |
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
9,360 | $38 | $134 |
| Pembrolizumab injection (Keytruda) | 7,400 | $42 | $139 |
| Denosumab injection (Prolia/Xgeva) | 5,760 | $18 | $68 |
| Iron infusion (Monoferric) | 3,700 | $17 | $72 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,030 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,350 | $1 | $122 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
927 | $8 | $35 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
504 | $102 | $224 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
304 | $67 | $148 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
272 | $11 | $93 |
| Pegfilgrastim-apgf injection An injection of pegfilgrastim-apgf, a biosimilar medication. The dose specified is 0.5 mg. |
264 | $85 | $879 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
253 | $13 | $105 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
199 | $111 | $686 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
161 | $1 | $7 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
147 | $53 | $304 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
144 | $57 | $205 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
119 | $55 | $334 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
113 | $61 | $157 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
109 | $25 | $152 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
70 | $1 | $19 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
68 | $108 | $297 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
58 | $95 | $232 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
57 | $48 | $281 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
56 | $144 | $301 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
54 | $133 | $343 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
54 | $1 | $9 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
52 | $17 | $97 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
49 | $24 | $156 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
28 | $75 | $251 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
26 | $27 | $249 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
24 | $2 | $19 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
24.7% high complexity
73.4% medium
1.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$37,858
Total received (2018-2024)
Avg $5,408/year across 7 years
Top 10% in PA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
49
Companies
192
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$5,322
2023
$9,150
2022
$7,701
2021
$4,886
2020
$6,111
2019
$3,423
2018
$1,264
Payments by company (2024)
GlaxoSmithKline, LLC.
$5,200
Astellas Pharma US Inc
$55
Ipsen Biopharmaceuticals, Inc
$27
PFIZER INC.
$24
Merck Sharp & Dohme LLC
$16
Top 3 companies account for 99.2% of 2024 payments
All-time payments by company (2018-2024) ›
Genentech USA, Inc.
$14,810
GlaxoSmithKline, LLC.
$7,040
E.R. Squibb & Sons, L.L.C.
$2,685
Celgene Corporation
$1,779
Bayer HealthCare Pharmaceuticals Inc.
$1,691
BeiGene USA, Inc.
$1,650
Janssen Biotech, Inc.
$1,628
Janssen Scientific Affairs, LLC
$1,515
Exelixis Inc.
$1,485
Foundation Medicine, Inc.
$1,050
Novartis Pharmaceuticals Corporation
$278
Novocure GmbH
$250
Amgen Inc.
$215
Pharmacyclics LLC, An AbbVie Company
$163
AstraZeneca Pharmaceuticals LP
$159
Merck Sharp & Dohme Corporation
$154
PFIZER INC.
$128
COMSORT, Inc
$100
Takeda Pharmaceuticals U.S.A., Inc.
$98
Astellas Pharma US Inc
$93
GENZYME CORPORATION
$87
SANOFI-AVENTIS U.S. LLC
$74
Incyte Corporation
$72
Daiichi Sankyo Inc.
$60
Clovis Oncology, Inc.
$51
Ipsen Biopharmaceuticals, Inc
$48
Lilly USA, LLC
$46
Dendreon Pharmaceuticals LLC
$46
Gilead Sciences, Inc.
$41
AbbVie, Inc.
$25
Regeneron Healthcare Solutions, Inc.
$24
JAZZ PHARMACEUTICALS INC.
$23
Advanced Accelerator Applications
$23
EISAI INC.
$22
Boehringer Ingelheim Pharmaceuticals, Inc.
$22
Helsinn Therapeutics (U.S.), Inc.
$20
Spectrum Pharmaceuticals Inc.
$19
Dova Pharmaceuticals
$19
Seagen Inc.
$17
Janssen Pharmaceuticals, Inc
$17
Rigel Pharmaceuticals, Inc.
$17
Pharmacosmos Therapeutics Inc.
$16
Merck Sharp & Dohme LLC
$16
EMD Serono, Inc.
$16
Prometheus Laboratories Inc.
$16
Kyowa Kirin, Inc.
$14
Seattle Genetics, Inc.
$14
Clinigen Inc
$11
Taiho Oncology, Inc.
$11
Top 3 companies account for 64.8% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AKYNZEO · ALIMTA · Abraxane · Alecensa · Aliqopa · Aranesp · Avastin · BRUKINSA · Bavencio · CABOMETYX · CALQUENCE · CEREZYME · CHANTIX · CYRAMZA · Cabometyx · Columvi · DARZALEX · Doptelet · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ERBITUX · Enhertu · FASLODEX · FOUNDATIONONE LIQUID · GAZYVA · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · INLYTA · INREBIC · Imbruvica · JADENU · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONOFERRIC · NINLARO · Neulasta · Nplate · OPDIVO · Onivyde · PADCEV · POLIVY · PROMACTA · PROVENGE · Proleukin · RENFLEXIS · Revlimid · Rubraca · SANCUSO · SPRYCEL · SUTENT · Somatuline Depot · TAGRISSO · TECENTRIQ · TECVAYLI · Tavalisse · VENCLEXTA · VOTRIENT · VYXEOS · Venclexta · Vitrakvi · XARELTO · XTANDI · Xospata · Xtandi · ZYTIGA · Zevalin
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
281
County median income
$111,521
Nearest hospital to ZIP centroid (approximate)
HORSHAM CLINIC
3.3 mi
3.3 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Seidman is a mixed practice specialist, with above-average Medicare volume (top 5% in PA), with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Seidman experienced with darbepoetin injection (aranesp) for anemia?
Based on Medicare claims data, Dr. Seidman performed 55,100 darbepoetin injection (aranesp) for anemia services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Seidman receive payments from pharmaceutical companies?
Yes. Dr. Seidman received a total of $37,858 from 49 companies across 192 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Seidman's costs compare to other hematology & oncology specialists in Horsham?
Dr. Seidman's average Medicare payment per service is $11. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Seidman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Horsham
Browse hematology & oncology specialists in Horsham ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in PA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in PA
Which PA hematology & oncology specialists receive the most from drug and device companies.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology